Nanotech Capital Raises in the U.S. – October 16th-31st, 2024

Some interesting transactions closed in the Nanotech sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.

PIPE

1. BioVie, a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers received $6.67 million of development capital through a private placement. The company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.

Later Stage VC

2. Terray Therapeutics, operator of a biotechnology company raised $120 million of Series B venture funding in a deal led by NVentures and Bedford Ridge Capital. The funds will be used to progress internal programs into clinical trials and further enhance the integrated AI platform, which is used to power both internal and partnered programs.

3. Forge Nano, developer of precision nano-coating technology raised $60.67 million of Series C venture funding in a deal led by Hanwha Aerospace Company. The fund will be used to build out a battery production line to meet the growing demand for premium batteries.

4. Ceramic Pro, manufacturer of ceramic coatings catering to multiple industrial segments raised venture funding. This funding is expected to enhance their product offerings and expand market reach.

Angel, Seed, and Grant

5. Archon Bio, operator of a biotechnology company intended to design self-assembling protein antibody nanomaterials for regenerative medicine and cancer raised $20 million of seed funding in a deal led by Opiant Pharmaceuticals.

#castleplacement #capitalraising #privateequity #venturecapital #investment #Nanotech

Jesus Tueme

Managing Director

Finance and banking executive with a global perspective, broad professional practice and extensive network in Latin America. 22 years at BBVA, BNPP and Credit Agricole. Successful deal-making track record with multinationals, major Latin American issuers and government agencies. Extensive experience in restructuring/special situations, initial public offerings, corporate strategy, evaluating alliances, mergers and acquisitions, corporate governance, risk management, customer centric and digital strategies, and financial analytics. BS in Economics from Mexico Monterrey Institute of Technology. MBA from the University of California Los Angeles in 1987. Graduated from Harvard Business School General Management Program. Further academic work on Risk Management at Stanford University and as a research and finance scholar at the Monterrey Institute of Technology.

  • Email: jtueme@castleplacement.com
  • (C) (646) 479-7616

Jesus Tueme

Jesus Tueme

Managing Director

Jesus Tueme

Managing Director

Please contact me if you have any questions or would like to discuss your capital raise:

Email: jtueme@castleplacement.com

(C) (646) 479-7616

Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement, LLC
1460 Broadway Street, Rte 400
New York, New York 10036
(212) 418-1188 | C: (516) 712-7784
kmargolis@castleplacement.com

Sending
42513